CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 397 enrolled
Drug / intervention
Esomeprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00401752
NCT00401752Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, 8 Week Comparative Efficacy and Safety Study of Esomeprazole 20 mg Every Day (qd) Versus Ranitidine 150 mg Twice a Day (Bid) in Patients With an NSAID-associated Gastric Ulcer When Daily NSAID is Continued

AstraZeneca·interventional·Posted Nov 22, 2006·Updated Jul 8, 2010

In Brief

A Phase 3 clinical trial evaluating Esomeprazole and Ranitidine for Gastric Ulcer. Completed, enrolled 397 participants across 9 sites in 2 countries.

Detailed Summary

The purpose of this study is to assess the efficacy of esomeprazole 20 mg dosed once daily and ranitidine 150 mg dosed twice daily through 4 weeks of treatment for the healing of gastric ulcers in patients receiving daily non-steroidal anti-inflammatory drug (NSAID)therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Ulcer
CountriesChina, Hong Kong
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 22, 2006
Enrollment StartMar 1, 2006
Study CompletionNov 1, 2008
TodayJul 2, 2026
Posted 19.6 years ago

Interventions

Esomeprazoledrug

Ranitidinedrug